Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage study, but that was less than previous trial results for Novo Nordisk's injectable obesity treatment Wegovy,

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded versions of the drug.

Sales of its blockbuster Wegovy obesity drug rose 67% over the period to 19.53 billion Danish kroner. Novo Nordisk last week cut its full-year guidance and named Mike Doustdar as its new CEO. Sales of Novo Nordisk's blockbuster Wegovy weight loss drug surged in the second quarter,